t:slim X2 insulin pump with Interoperable Technology, Control-IQ+ technology, REF: 1014070, 10140...
FDA Device Recall #Z-0232-2026 — Class II — August 5, 2025
Recall Summary
| Recall Number | Z-0232-2026 |
| Classification | Class II — Moderate risk |
| Date Initiated | August 5, 2025 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Tandem Diabetes Care, Inc. |
| Location | San Diego, CA |
| Product Type | Devices |
| Quantity | 122,958 |
Product Description
t:slim X2 insulin pump with Interoperable Technology, Control-IQ+ technology, REF: 1014070, 1014071, 1014072, 1014073, and User Guide when using Dexcom G7 sensor; Tandem Mobi insulin pump with Interoperable Technology, Control-IQ+ technology, REF: 1014801, 1014811, 1014813, and User Guide when using Dexcom G7 sensor
Reason for Recall
A software defect in versions 7.9.0.1 and 7.10.1 of the pump software for Tandem t:slim X2 and version 7.9.0.1 of the Tandem Mobi pump with Control-IQ+ technology that are paired with a G7 sensor may result in an unexpected automatic insulin correction bolus (autobolus ) which could result in hypoglycemia.
Distribution Pattern
US nationwide distribution including Puerto Rico.
Lot / Code Information
t:slim X2, UDI-DI: 00389152407012, 00389152407111, 00389152407210, 00389152407319 with software versions 7.9.0.1 and 7.10.1, User Guide versions not including and prior to: AW-1014562 Revision D; Tandem Mobi, UDI-DI: 00389152480114, 00389152481111, 00389152481319 with software version 7.9.0.1, User Guide versions not including and prior to: AW-1014938 Revision C
Other Recalls from Tandem Diabetes Care, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-1636-2026 | Class II | Tandem pumps are battery-operated infusion pump... | Jan 30, 2026 |
| Z-0427-2026 | Class I | Tandem Mobi Insulin Pump: Description/Catalog:... | Oct 6, 2025 |
| Z-2343-2025 | Class I | Battery Operated infusion pumps. t:slim X2 G5, ... | Jul 21, 2025 |
| Z-2621-2025 | Class II | t:slim X2 Insulin Pump with Interoperable Techn... | Jul 3, 2025 |
| Z-1519-2025 | Class I | t:slim X2 Insulin Pump with Interoperable Techn... | Feb 27, 2025 |
Frequently Asked Questions
A software recall means the device's embedded software or firmware has a defect that could affect its performance or safety. Many software recalls are corrected through firmware updates that can be applied without physically replacing the device. For implantable devices, the update may be delivered wirelessly during a routine clinic visit. For external devices, the manufacturer may provide updated software files or replacement units. Contact your healthcare provider to determine whether your specific device and software version are affected and what action is recommended.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.